flipping the script

Research Funded

$5,000,000+

We have funded over $5M in brain cancer research grant proposals

40+

We have funded over 40 clinical trials / research grants

25+

We have partnered with over 25 leading institutions across the country to fund innovative research

Featured Research

Grants & Research Funded

UC San Diego
2024

UCSD

$60,000 granted
Year 2 of postdoctoral fellowship focused on targeting bromodomain containing two protein to inhibit mesenchymal transition in recurrent glioblastoma.
Dr. Vadla
In partnership with American Association for Cancer Research (AACR)
UCLA Health
2023

UCLA

$25,000 granted
Investigation of anti-angiogenic treatment resistance in glioblastoma.
Dr. Yang
In partnership with The Musella Foundation
UI Health
2023

UIllinois Cancer Center

$25,000 granted
Targeting of glioblastoma stem cells by miRNA.
Dr. Yamada
 In partnership with The Musella Foundation
Harvard Medical School
2023

Harvard Medical School

$35,000 granted
Computer modeling of tumor treating fields.
Dr. Haack
 In partnership with The Musella Foundation
StacheStrong Glioblastoma Brain Cancer Research Grant with Glioma Connectome Project
2021 - 2023

Glioma Connectome Project (GCP)

$643,786 granted
8 leading research centers (Henry Ford, Lenox Hill, Northwestern, UMiami, UNebraska, UPenn, UPMC, UTexas-Houston) use machine learning to improve brain tumor patient care by analyzing brain organization (connectomics) and patient experience data.
Columbia University
2023

Columbia University

$25,000 granted
Test blocking of the CD47/SIRPa pathway during radiation.
Dr. Gartrell
 In partnership with The Musella Foundation
UChicago
2023

UChicago

$50,000 granted
Creation of a peptide vaccine targeting multiple cytomegalovirus antigens in malignant brain tumors.


Dr. Thompson
 In partnership with The Musella Foundation
UCLA Health
2023

UCLA

$200,000 granted
Testing two clinical drugs to determine if they promote GBM cell death in preclinical GBM models.
Dr. Nathanson and Dr. Cloughhesy
 In partnership with National Brain Tumor Society (NBTS)
Duke
2023

Duke

$100,000 granted
Glioblastoma biobank project, which Includes a survey portal for GBM patients to collect medical history and demographics, while also including blood and serum collection for genetic analysis.
Dr. Ostrom and Dr. Walsh
 In partnership with Glioblastoma Research Organization (GBMRO)
UC San Diego
2023

UCSD

$66,000 granted
Postdoctoral fellowship focused on targeting bromodomain containing two protein to inhibit mesenchymal transition in recurrent glioblastoma.
Dr. Vadla
 In partnership with American Association for Cancer Research (AACR)
UCSF
2023

UCSF & Brigham and Women's

$200,000 granted
Clinical study to test the safety and feasibility of implanting a microdevice into GBM patients’ tumors to deliver microdoses of up to 20 different drugs into different areas in the tumor. The tumor and device would then be removed to assess the tumor biomarkers and response to the drugs.
Dr. Hervey-Jumper and Dr. Jones
 In partnership with American Brain Tumor Association (ABTA)
Weill Cornell
2022

Weill Cornell

$40,023 granted
Targeting cancer-associated fibroblasts in irradiated pediatric brain tumors.

Dr. Vanpouille-Box
“Solely funded by StacheStrong”
brigham-womens-hospital
2022

Brigham and Women’s

$200,000 granted
Development of therapeutic miR-10b gene editing. MiR-10b is highly abundant in adult gliomas and appears to be essential for the viability of glioma cells. This study is anticipated to present a common therapeutic strategy for GBM and other gliomas.
Dr. Krichevsky
 In partnership with American Brain Tumor Association (ABTA)
StacheStrong Glioblastoma Brain Cancer Research Grant with society of Neurological Surgeons
2022

Society of Neurological Surgeons

$110,000 granted
Launched Society of Neurological Surgeons (SNS) Training Program: Formal mentored research program for 2 years for neurosurgery residents. Goal is to improve human health by providing participants with the skills, mentorship, education and experience needed.
Ivy Brain Tumor Center
2021

Ivy Brain Tumor Center

$340,000 granted
Phase 0/1 clinical trial of sonodynamic therapy for patients with recurrent glioblastoma multiforme and recurrent high-grade gliomas. This novel drug-device combination has the potential to become a new treatment modality for patients with brain cancer.
Dr. Sanai
In partnership with Barrow Neurological Foundation
Duke
2021

Duke

$148,620 granted
Assess how individual cells evolve and adapt over time and in response to therapy. Gene expression profiling at this level will aid in the identification of particular therapeutic sensitivities that may be present and otherwise unseen based on traditional sequencing methods.
Dr. Pirozzi
“Solely funded by StacheStrong”
Yale
2021

Yale

$1,000,000 granted
Support NBTS’ launch of the targeting DNA damage response in glioma (TDG) consortium. This is a collaboration of world-class researchers advancing an emerging and promising, but underdeveloped, area of cancer research.
Dr. Bindra
 In partnership with National Brain Tumor Society (NBTS)
UMiami
2021

UMiami

$50,000 granted
Discovery grant investigating the role of CD97/ADGRE5 receptor in glioblastoma invasion and its mechanism of action in the brain.
Dr. Eichberg
In partnership with Neurosurgery Research & Education Foundation (NREF)
UCSF
2021

UCSF

$50,000 granted
Discovery grant focused on in vivo gene screening and transcriptome editing with retroviral-delivered CRISPR-Cas for the treatment of glioblastoma.
Dr. Young
In partnership with Neurosurgery Research & Education Foundation (NREF)
northwestern medicine
2020

Northwestern

$50,000 granted
Developing a patient-derived b-cell-based vaccine, a novel therapeutic agent for glioblastomas.
Dr. Castro
In partnership with Neurosurgery Research & Education Foundation (NREF)
Mount Sinai NYC
2020

Mount Sinai NYC

$100,000 granted
Trial evaluated the safety, efficacy, and feasibility of delivering a therapeutic vaccine to patients made up of their own dendritic cells (isolated from blood samples), loaded with individualized multiple neoantigens made from synthetic peptides created in the laboratory and based on the specific alterations found in a patient’s tumor tissue.
Dr. Hormigo
In partnership with National Brain Tumor Society (NBTS)
GBM Agile
2019

GBM Agile

$500,000 granted
Assist in the operationalization and launch of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), the world’s first global “adaptive” clinical trial for brain cancer.